| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-07-01 | ImmunID (France) Singapore Immunology Network (SIgN) (Singapore) | ImmunTraCkeR® and ImmunIG® tests | undisclosed | R&D collaboration |
Diagnostic | R&D agreement |
| 2014-07-01 | Onkaido Therapeutics, Moderna Therapeutics' company (USA - MA) | president | nomination | Cancer - Oncology | Nomination | |
| 2014-06-30 | Illumina (USA -CA) Biomnis (France) | HiSeq 2500 and consumables to develop and perform non-invasive prenatal testing (NIPT) | services |
Technology - Services | Services contract | |
| 2014-06-30 | Illumina (USA -CA) Genoma (Italy) | HiSeq 2500 and consumables to develop and perform non-invasive prenatal testing (NIPT) | services |
Technology - Services | Services contract | |
| 2014-06-30 | Illumina (USA - CA) The Center for Human Genetics and Laboratory Diagnostics Martinsried (Germany) | HiSeq 2500 and consumables to develop and perform non-invasive prenatal testing (NIPT) | services |
Technology - Services | Services contract | |
| 2014-06-30 | Tiziana Life Sciences (UK) TTFactor (Italy) | twenty defined stem cell markers (TOP 20) for patient stratification in breast cancer | licensing |
Cancer - Oncology | Licensing agreement | |
| 2014-06-30 | TTFactor (Italy) Gensignia (UK) | microRNA signatures | lung cancer, breast cancer, ovarian cancer and other cancers | collaboration R&D |
Diagnostic - Cancer - Oncology | Collaboration agreement |
| 2014-06-30 | Vectura (UK) undisclosed US partner (USA) | VR506 | asthma | collaboration development licensing |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Development agreement |
| 2014-06-30 | RedHill Biopharma (Israel) Wilex (Germany) | Mesupron® (upamostat) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2014-06-30 | Boston Strategics Corporation, now Strategia Therapeutics (USA - MA) Eisai (Japan) | E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione)] | FLT3 mutated acute myeloid leukemia (AML) and other oncology indications | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-06-26 | Debiopharm (Switzerland) Nobelex Biotech (Canada) | antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action | Neisseria gonorrhoeae and enteric species infections | development |
Infectious diseases | Development agreement |
| 2014-06-26 | Roche (Switzerland) Stratos Genomics (USA - WA) | Xpandomers™ | Technology - Services | R&D agreement | ||
| 2014-06-26 | Liomont (Mexico) Oncobiologics (USA - NJ) | two undisclosed biosimilar monoclonal antibody products | development manufacturing production commercialisation |
Development agreement | ||
| 2014-06-26 | Nuevolution (Denmark) | corporate advisor | nomination | Technology - Services | Nomination | |
| 2014-06-25 | Oasmia Pharmaceutical (Sweden) global pharmaceutical company | XR-17 | R&D |
R&D agreement | ||
| 2014-06-24 | Debiopharm (Switzerland) TCG Lifesciences (India) | antibiotics targeting drug-resistant bacteria for community hospital-acquired infections | community hospital-acquired infections | development |
Infectious diseases | Development agreement |
| 2014-06-24 | Merck KGaA, Merck Serono (Germany) Mersana Therapeutics (USA - MA) | next-generation antibody-drug conjugates (ADCs) | development |
Cancer - Oncology | Development agreement | |
| 2014-06-24 | Oasmia Pharmaceutical (Sweden) Baxter (USA - IL) | Paclical, Paccal Vet®-CA1, future Oasmia products | Cancer - Oncology | Production agreement | ||
| 2014-06-23 | Roche (Switzerland) Inception Sciences (USA - CA) Versant Venture (USA - PA) | novel small molecule remyelinating therapies | multiple sclerosis | collaboration |
Autoimmune diseases - Neurodegenerative diseases | Collaboration agreement |
| 2014-06-23 | ProBioGen (Germany) Novartis (Switzerland) | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Technology - Services | Licensing agreement |
